Skip to content

Cancer Genetics and Genomics Laboratory

BC Cancer

  • Home
  • Hematological
    • Acute Lymphoblastic Leukemia (Ph positive)
    • Acute Myeloid Leukemia (AML)
    • Acute Promyelocytic Leukemia (APL)
      • APL – FISH (Dx)
      • APL – RT-ddPCR (MRD)
      • APL – RTPCR
    • Chimerism
    • Chronic Lymphocytic Leukemia/Lymphoma (CLL)
    • Chronic Myeloid Leukemia (CML)
      • CML – FISH (Dx)
      • CML – QRTPCR
      • CML – RTPCR
      • CML – Kinase Domain
    • Lymphoma
      • Anaplastic Large Cell
      • Burkitt
      • Follicular
      • High-Grade B-Cell
      • IRF4 B-Cell Lymphoma
      • MALT
      • Mantle Cell
      • NHL – B/T-cell Clonality
    • Lymphoid and Myeloid Neoplasm with Eosinophilia
    • Multiple Myeloma
    • Myelodysplastic Syndrome (MDS)
    • Myeloproliferative Neoplasm (MPN)
  • Solid Tumour
    • Colorectal Cancer
      • OncoPanel
      • BRAF V600
    • CNS
      • Focus Panel
      • Glioblastoma Multiforme (GBM)
      • Oligodendroglioma (ODG) 1p/19q FISH
    • Lung Cancer
      • ALK FISH
      • EGFR T790M (Plasma)
      • Focus Panel
      • ROS1 FISH
    • Melanoma
      • OncoPanel
      • Focus Panel
      • BRAF V600
    • Sarcoma
      • Alveolar Rhabdomyosarcoma (ARMS)
      • Clear Cell Sarcoma
      • Dermatofibrosarcoma protuberens (DFSP)
      • Ewing Sarcoma
      • Liposarcoma
      • Low Grade Fibromyxoid Sarcoma
      • Myxoid Liposarcoma
      • Synovial Sarcoma
    • Prostate Cancer
      • OncoPanel
    • DPYD Screening
  • Hereditary
    • Mainstreamed Hereditary Cancer Testing
  • Genes/Probes/Panels
    • Hereditary Cancer Panel
    • Myeloid Panel
    • OncoPanel
    • Focus Panel
    • Gene/Probe List
  • Guidelines
    • Specimens
    • Variants
    • FAQ
  • Studies
    • PREDICTm
    • [CLOSED]
  • Requisitions
  • Updates
  • Contact

Changes to Mainstreamed Hereditary Cancer Testing Result Reporting

2023/11/24 by Curtis Hughesman

This memo is to tell you about upcoming changes to how results of mainstreamed genetic testing will be
shared with ordering clinicians and patients from the Cancer Genetics and Genomics Laboratory (CGL)
and the Hereditary Cancer Program (HCP).

Mainstreaming December Memo Draft_FINALDownload
Categories Uncategorized
Focus Panel for Early Stage NSCLC
PREDiCTm study changes
© 2025 Cancer Genetics and Genomics Laboratory • Built with GeneratePress